Literature DB >> 4271629

Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein.

C G Cochrane, S D Revak, K D Wuepper.   

Abstract

The activation of Hageman factor in solid and fluid phase has been analyzed. Activation of highly purified Hageman factor occurred after it interacted with and became bound to a negatively charged surface. Activation was observed in the absence of enzymes that are inhibitable with diisopropylfluorophosphate, phenyl methyl sulfonyl fluoride and epsilon-amino-n-caproic acid. The binding of [(125)I]Hageman factor to the negatively charged surface was markedly inhibited by plasma or purified plasma proteins. Activation of Hageman factor in solution (fluid phase) was obtained with kallikrein, plasmin, and Factor XI (plasma thromboplastin antecedent). Kallikrein was greater than 10 times more active in its ability to activate Hageman factor than plasmin and Factor XI. The data offer a plausible explanation for the finding that highly purified kallikrein promotes clotting of normal plasma. In addition, the combined results of this and previously reported data from this laboratory indicate that the reciprocal activation of Hageman factor by kallikrein in fluid phase is essential for normal rate of activation of the intrinsic-clotting, kinin-forming, and fibrinolytic systems. Activation of Hageman factor was associated with three different structural changes in the molecule: (a) Purified Hageman factor, activated on negatively charged surfaces retained its native mol wt of 80-90,000. Presumably a conformational change accompanied activation. (b) In fluid phase, activation with kallikrein and plasmin did not result in cleavage of large fragments of rabbit Hageman factor, although the activation required hydrolytic capacity of the enzymes. (c) Activation of human Hageman factor with kallikrein or plasmin was associated with cleavage of the molecule to 52,000, 40,000, and 28,000 mol wt fragments. Activation of rabbit Hageman factor with trypsin resulted in cleavage of the molecule into three fragments, each of 30,000 mol wt as noted previously. This major cleavage occurred simultaneously with activation.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4271629      PMCID: PMC2139466          DOI: 10.1084/jem.138.6.1564

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

2.  The kinin system of human plasma. VI. The action of plasmin.

Authors:  C E Burrowes; H Z Movat; M J Soltay
Journal:  Proc Soc Exp Biol Med       Date:  1971-12

3.  The interaction of Hageman factor and immune complexes.

Authors:  C G Cochrane; K D Wuepper; B S Aiken; S D Revak; H L Spiegelberg
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

4.  Fletcher factor deficiency: a report of three unrelated cases.

Authors:  P G Hattersley; D Hayse
Journal:  Br J Haematol       Date:  1970-04       Impact factor: 6.998

5.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

6.  Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties.

Authors:  W E Hathaway; L P Belhasen; H S Hathaway
Journal:  Blood       Date:  1965-11       Impact factor: 22.113

7.  Inhibition of Hageman factor activation.

Authors:  H L Nossel; H Rubin; M Drillings; R Hsieh
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

8.  The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman Factor).

Authors:  C G Cochrane; K D Wuepper
Journal:  J Exp Med       Date:  1971-10-01       Impact factor: 14.307

9.  Plasma prekallikrein: isolation, characterization, and mechanism of activation.

Authors:  K D Wuepper; C G Cochrane
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

10.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

View more
  55 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

2.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

3.  Competitive-protein adsorption in contact activation of blood factor XII.

Authors:  Rui Zhuo; Christopher A Siedlecki; Erwin A Vogler
Journal:  Biomaterials       Date:  2007-07-20       Impact factor: 12.479

Review 4.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

5.  Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.

Authors:  H L Meier; J V Pierce; R W Colman; A P Kaplan
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

Review 6.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

7.  The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule.

Authors:  S D Revak; C G Cochrane
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

8.  Association of factor XI and high molecular weight kininogen in human plasma.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

9.  Direct evidence for the location of kallikrein in the striated ducts of the cat's submandibular gland by the use of specific antibody.

Authors:  Y Hojima; B Maranda; C Moriwaki; M Schachter
Journal:  J Physiol       Date:  1977-07       Impact factor: 5.182

10.  Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis.

Authors:  Yves Decrem; Géraldine Rath; Virginie Blasioli; Philippe Cauchie; Séverine Robert; Jérôme Beaufays; Jean-Marie Frère; Olivier Feron; Jean-Michel Dogné; Chantal Dessy; Luc Vanhamme; Edmond Godfroid
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.